ICD-10-PCS › X
ICD-10-PCS codes starting with X
734 codes, page 8 of 8. Every code ever valid for billing is listed, including those now retired.
| Code | Description | Status |
|---|---|---|
| XX2F3W9 | Monitoring of Musculoskeletal Muscle Compartment Pressure, Micro-Electro-Mechanical System, Percutaneous Approach, New Technology Group 9 | Valid |
| XX2KXDB | Monitoring of Interstitial Glucose, Wearable Sensor, External Approach, New Technology Group 11 | Valid |
| XX2KXP9 | Monitoring of Interstitial Fluid Volume, Sub-Epidermal Moisture using Electrical Biocapacitance, External Approach, New Technology Group 9 | Valid |
| XXA | New Technology, Physiological Systems, Assistance | Not billable |
| XXA536A | Circulatory Filtration, Blood Pathogens, Percutaneous Approach, New Technology Group 10 | Valid |
| XXA539B | Circulatory Filtration, Ticagrelor, Percutaneous Approach, New Technology Group 11 | Valid |
| XXE | New Technology, Physiological Systems, Measurement | Not billable |
| XXE0X07 | Measurement of Intracranial Vascular Activity, Computer-aided Assessment, New Technology Group 7 | Valid |
| XXE0X1A | Measurement of Intracranial Cerebrospinal Fluid Flow, Computer-aided Triage and Notification, New Technology Group 10 | Valid |
| XXE0X48 | Measurement of Brain Electrical Activity, Computer-aided Semiologic Analysis, New Technology Group 8 | Valid |
| XXE2X19 | Measurement of Cardiac Output, Computer-aided Assessment, New Technology Group 9 | Valid |
| XXE2XHC | Measurement of Cardiac Conduction Mechanism, Computer-aided Mapping for Planning, New Technology Group 12 | Valid |
| XXE3X27 | Measurement of Pulmonary Artery Flow, Computer-aided Triage and Notification, New Technology Group 7 | Valid |
| XXE3X58 | Measurement of Coronary Artery Flow, Quantitative Flow Ratio Analysis, New Technology Group 8 | Valid |
| XXE3X68 | Measurement of Coronary Artery Flow, Computer-aided Valve Modeling and Notification, New Technology Group 8 | Valid |
| XXE5X2A | Measurement of Infection, Phenotypic Fully Automated Rapid Susceptibility Technology with Controlled Inoculum, New Technology Group 10 | Valid |
| XXE5X38 | Measurement of Infection, Whole Blood Reverse Transcription and Quantitative Real-time Polymerase Chain Reaction, New Technology Group 8 | Valid |
| XXE5X4A | Measurement of Infection, Positive Blood Culture Small Molecule Sensor Array Technology, New Technology Group 10 | Valid |
| XXE5X5A | Measurement of Immune Response, Whole Blood Cellular Assessment via Microfluidic Deformability, New Technology Group 10 | Valid |
| XXE5XBB | Measurement of Infection and Immune Response, Gene Expression Testing System, New Technology Group 11 | Valid |
| XXE5XM5 | Measurement of Infection, Whole Blood Nucleic Acid-base Microbial Detection, New Technology Group 5 through FY2024 | Retired |
| XXE5XN6 | Measurement of Infection, Positive Blood Culture Fluorescence Hybridization for Organism Identification, Concentration and Susceptibility, New Technology Group 6 through FY2025 | Retired |
| XXE5XR7 | Measurement of Infection, Mechanical Initial Specimen Diversion Technique Using Active Negative Pressure, New Technology Group 7 through FY2026 | Retired |
| XXE5XT7 | Measurement of Intracranial Arterial Flow, Whole Blood mRNA, New Technology Group 7 through FY2026 | Retired |
| XXE5XV7 | Measurement of Infection, Serum/Plasma Nanoparticle Fluorescence SARS-CoV-2 Antibody Detection, New Technology Group 7 | Valid |
| XXE5XY9 | Measurement of Infection, Other Positive Blood/Isolated Colonies Bimodal Phenotypic Susceptibility Technology, New Technology Group 9 | Valid |
| XXE97U7 | Measurement of Infection, Nasopharyngeal Fluid SARS-CoV-2 Polymerase Chain Reaction, New Technology Group 7 | Valid |
| XXEBXQ6 | Measurement of Infection, Lower Respiratory Fluid Nucleic Acid-base Microbial Detection, New Technology Group 6 through FY2025 | Retired |
| XXEZXAB | Measurement of Macronutrient Content, Computer-aided Assessment for Nutrition Management, New Technology Group 11 | Valid |
| XXEZXCB | Measurement of Infection, Computer-aided Triage and Notification, New Technology Group 11 | Valid |
| XY0 | New Technology, Extracorporeal, Introduction | Not billable |
| XY0VX83 | Extracorporeal Introduction of Endothelial Damage Inhibitor to Vein Graft, New Technology Group 3 | Valid |
| XY0YX28 | Extracorporeal Introduction of Taurolidine Anti-infective and Heparin Anticoagulant, New Technology Group 8 | Valid |
| XY0YX37 | Extracorporeal Introduction of Nafamostat Anticoagulant, New Technology Group 7 | Valid |
Previous Page 8 of 8